Professor Chloe Orkin (Queen Mary University London, UK) joins Peter Hayward to talk about long-acting cabotegravir for HIV treatment and the 96 weeks of the FLAIR study.
Read the full article:
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30340-4/fulltext
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv